Supplementary Information

General.

Protected amino acids Fmoc-L-Dap(Boc)-OH and Fmoc-L-Orn(Boc)-OH were purchased from Chemimpex, and, Fmoc-L-Dab(Boc)-OH from GL Biochem. Solvents and other reagents were purchased from Sigma Aldrich and used without further purification. Biotage Initiator Eight microwave reactor system was used for all reactions. Jasco P1010 Polarimeter was used to measure optical rotation. Analytical LC/MS was performed on an Agilent 1200 Series system with a single quadrupole mass spectrometer (6110), a UV detector operating at 210 nm and an ELSD detector, and using an analytical reverse phase column (Eclipse XDB-Phenyl, 5 µm, 4.6x150 mm), flow rate 1 mL/min. Alternatively LCMS analysis was performed using a Shimadzu Prominence system using an Agilent Zorbax Eclipse XDB-Phenyl column maintained at 40°C with SPD-M20A diode array UV-Vis detector, ELSD -LT II evaporative light scattering detector and LCMS-2020 mass spectrometer. Reverse phase eluent for analytical purposes was effected using an appropriate gradient from water (0.05% formic acid) and acetonitrile (0.05% formic acid), flow rate of 1 ml/min. High resolution mass spectra were obtained on a Bruker micrOTOF 232. NMR spectra were obtained on a Bruker 600 MHz.

Experimental Procedures.

Synthesis of 4, 7 and 8:



Example of **4**:

To Fmoc-L-Dab(Boc)-OH (2 mmol, 881 mg) in a microwave reactor tube with a magnetic stirrer, was added solid paraformaldehyde (4 mmol, 133 mg), camphorsulfonic acid (0.17 mmol, 40 mg, 8.6mol%) and acetonitrile (10 mL). The tube was then sealed and subjected to a 2 min run at 120 °C (microwave settings at 400 Watts). Resulting cooled mixture was concentrated under vacuo and put through a short silica pad using ethyl acetate and petroleum spirits (3:7) as eluent, dried with MgSO₄ and finally concentrated under vacuo to give a colourless oily residue. Lyophilisation from water/acetonitrile (1:1) yields a white powder of respective compound **4**, **7** and **8**. The powders of compounds **4**, **7** and **8** are air sensitive and become oils within minutes and thus requires N₂ atmosphere or cooled conditions for storage.

4: FL_7023_74_1 (Trans/Cis isomers) ¹H NMR (600 MHz, CDCl₃): 1.48 (br, s, 9H); 2.00-2.22 (br, m, 2H); 2.96, 3.09, 3.95 (br, 2H); 4.22-4.38 (br, m, 1H); 4.40-4.50 (br, 2H); 4.64 (br, 1H); 5.00 (br, 1H); 7.34 (m, 2H); 7.39 (br, 2H); 7.51 (br, m, 1H); 7.62 (br, 1H); 7.76 (br, 2H). ¹³C NMR (150.9 MHz, CDCl₃): 25.6 (s), 28.3 (s), 39.6 (br), 47.0 (s), 53.0 (s), 67.5 (s), 68.5 (br), 80.9 (s), 119.9 (s), 124.9 (s), 127.2 (s), 128.1 (s), 141.4 (s), 143.7 (s), 154.0 (br), 155.2 (s), 175.4 (br, s). MS: m/z 453 [M+H]⁺, 353 [M-Boc]⁺. HRMS calculated for C₂₅H₂₈N₂O₆Na: 475.1840. Found 475.1860.

7: FL_7292_36_1 (Trans/Cis at Fmoc amide bond) ¹H NMR (600 MHz, CDCl₃): 1.49 (s, 9H); 3.78, 3.98 (m, 2H); 4.20, 4.30 (m, 1H); 4.38, 4.67 (m, 1H); 4.44, 4.54 (m, 2H); 4.78, 4.84 (m, 2H); 7.33 (m, 2H); 7.41 (t, 2H); 7.54 (m, 2H); 7.56 (m, 2H); 7.74 (m, 2H); 7.78 (m, 2H). ¹³C NMR (150.9 MHz, CDCl₃): 28.2 (s), 47.0 (br), 47.1 (s), 48.0 (br), 56.3 (br), 60.2 (s), 67.8 (s), 120.1 (s), 124.8 (d), 125.0 (d), 127.1 (s), 127.8 (s), 127.9 (s), 141.3 (s), 143.5 (m), 152.8 (s), 173.4 (s). MS: m/z 439 [M+H]⁺, 339 [M-Boc]⁺. HRMS calculated for C₂₄H₂₆N₂O₆Na: 461.1683. Found 461.1699.

8: FL-7292-35-1 ¹H NMR (600 MHz, CDCl₃): 1.46 (br, s, 9H); 1.76, 1.86 (br, m, 2H); 2.09, 2.24 (br, m, 2H); 3.29, 3.51 (br, m, 2H); 4.2-4.35 (br, 1H); 4.47, 4.77 (br, 1H); 4.51 (m, 2H); 4.97-5.19 (m, 2H); 7.35 (br, 2H); 7.43 (br, 2H); 7.58 (br, 2H); 7.79

(br, 2H). ¹³C NMR (150.9 MHz, CDCl₃): 25.7 (s), 27.5 (s), 28.2 (br), 46.4 (s), 47.1 (s), 57.6 (s), 58.1 (s), 67.7 (s), 120.0 (s), 125.1 (s), 127.0 (s), 127.8 (s). MS: m/z 467 [M+H]⁺, 367 [M-Boc]⁺. HRMS calculated for C₂₆H₃₁N₂O₆: 467.2177. Found 467.2165.

Synthesis of 9 – 11:



Example of 10:

To crude 4 (2.2 mmol, 100 mg) in a 1 mL vial with a stirrer bar was added triethylsilane (12 mmol, 0.2 mL), trifluoroacetic acid (0.2 mL) and chloroform (0.2 mL). The mixture was sealed and stirred for 8 h at ambient temperature. LCMS analysis revealed full conversion of starting material and addition of a new single peak corresponding to the desired product. The crude mixture was then concentrated under vacuo followed by drying on a high vacuum set up (~2 h) to yield 75 mg (96 %) of a bright yellow oil. Compounds 9 and 11 required 8 h at 60 °C for complete conversion. Lyophilisation from water/acetonitrile (1:1) yields a white powder of respective compound 9 - 11. The powders of compounds 9 – 11 are air sensitive and become oils within minutes and thus requires N₂ atmosphere or cooled conditions for storage.

9: FL_7292_51_8_14 ¹H NMR (600 MHz, CDCl₃): 2.16-2.21 (br, m, 2H); 2.67 (s, 3H); 3.04, 3.17 (br, m, 2H); 4.15 (br, 1H); 4.33 (br, m, 1H); 4.20 (t, J = 6.92 Hz, 2H); 4.35 (d, J = 6.92 Hz, 2H); 6.33 (d, 3J = 4.67 Hz, 1H); 7.30 (t, J = 7.52 Hz, 2H); 7.40 (t, J = 7.52 Hz, 2H); 7.60 (t, J = 8.20 Hz, 2H); 7.80 (d, J = 7.50 Hz, 2H). ¹³C NMR (150.9 MHz, CDCl₃): 30.2 (s), 33.3 (s), 47.1 (s), 47.7 (s), 54.2 (s), 67.2 (s), 120.3 (s), 125.2 (s), 127.1 (s), 127.8 (s), 141.3 (s), 143.8 (s), 144.0 (s), 156.6 (s), 176.0 (s). MS:

m/z 355 [M+H]+. HRMS calculated for $C_{20}H_{23}N_2O_4$: 355.1652. Found 355.1643. [α]_D²⁰ +20±0.74 (*c* 0.033, CHCl₃)

10: FL_7292_52_10_14 ¹H NMR (600 MHz, DMSO-d₆): 2.54 (s, 6H); 2.86, 3.04 (m, 2H); 3.79 (m, 1H); 4.24 (m, 1H); 4.25, 4.30 (m, 2H); 6.87 (d, 3J = 6.63 Hz, 1H); 7.34 (m, 2H); 7.42 (t, 2H); 7.71 (m, 2H); 7.89 (d, J = 7.9 Hz, 2H). ¹³C NMR (150.9 MHz, DMSO-d₆): 33.4 (s), 47.1 (s), 50.5 (s), 50.8 (s), 66.2 (s), 120.6 (s), 125.7 (d), 127.6 (s), 128.1 (s), 141.2 (s), 144.3 (s), 144.4 (s), 156.2 (s), 171.6 (s). MS: m/z 341 [M+H]⁺. HRMS calculated for C₁₉H₂₁N₂O₄: 341.1496. Found 341.1510. [α]_D²⁰ +87±0.95 (*c* 0.112, MeOH)

11: FL-7292-43-1 ¹H NMR (600 MHz, CDCl₃): 1.77 (br, 2H); 1.77-1.91 (br, 2H); 2.62 (br, s, 3H); 2.94 (br, m, 2H); 4.14-4.24 (br, 1H); 4.01, 4.29 (br, 1H); 4.30-4.46 (m, 2H); 7.26 (br, 2H); 7.35 (t, J = 7.92 Hz, 2H); 7.51 (br, 2H); 7.71 (d, J = 7.3 Hz, 2H). ¹³C NMR (150.9 MHz, CDCl₃): 21.9 (br), 28.0 (br), 33.3 (s), 47.1 (s), 49.2 (br), 53.2 (s), 67.4 (s), 120.1 (s), 125.2 (br), 127.3 (s), 127.8 (s), 141.3 (s), 143.5 (s), 143.6 (s), 156.8 (s), 175.0 (s).MS: m/z 369 [M+H]⁺. HRMS calculated for C₂₁H₂₅N₂O₄: 369.1809. Found 369.1807. +33±1.17 (*c* 0.1264, MeOH)

Synthesis of 12 – 14:



Example of 12:

Crude 4 (0.146 mmol, 66 mg) was stirred in neat formic acid (0.5 mL) for 2 h followed by concentration under vacuo to form an oil. To this residue was added MeOH (2 mL) and 1,4-dioxane (6 drops) and aqueous formaldehyde (0.876 mmol, 0.064 mL). The mixture turned milky. Sodium cyanoborohydride (0.31 mmol, 19.3

mg, 2.1 eq) was then added in portions during 2 min. The mixture turned transparent and then back to milky. LCMS analysis of the reaction mixture revealed full conversion after 15 min and the mixture was concentrated under vacuo. To this residue was added triethylsilane (0.876 mmol, 0.14 mL), trifluoroacetic acid (0.14 mL) and chloroform (0.14 mL) followed by heating for 8 h at 60 °C. LCMS analysis revealed full conversion of starting material and addition of a new single peak corresponding to the desired product 12. Yield 52 mg (97 %) with a purity >95 % (LCMS). Compounds 13 and 14 required 3 h at 100 °C for full conversion giving similar yields and purity in both cases. Lyophilisation from water/acetonitrile (1:1) yields a white powder of respective compound 12 - 14. The powders of compounds 12 - 14 are air sensitive and become oils within minutes and thus requires N₂ atmosphere or cooled conditions for storage.

12: FL_7292-50-1 ¹H NMR (600 MHz, CDCl₃): 2.12, 2.33 (br, m, 2H); 2.74 (s, 3H); 3.00, 3.19 (br, m, 2H); 4.07 (br, 1H); 4.25 (t, J = 6.88 Hz, 1H); 4.38 (m, 2H); 6.31 (br, 1H); 7.35 (t, J = 7.60 Hz, 2H); 7.44 (t, J = 7.60 Hz, 2H); 7.65 (t, J = 6.66 Hz, 2H); 7.80 (d, J = 7.29 Hz, 2H). ¹³C NMR (150.9 MHz, DMSO-d₆): 29.3 (br), 44.2 (s), 47.1 (s), 54.5 (s), 56.3 (s), 66.1 (s), 120.7 (s), 125.8 (s), 127.6 (s), 128.0 (s), 140.6 (s), 141.4 (s), 144.3 (s), 150.0 (br), 173.7 (br). MS: m/z 369 [M+H]⁺. HRMS calculated for C₂₁H₂₅N₂O₄: 369.1809. Found 369.1796. [α]_D²⁰ +60±0.66 (*c* 0.15, CHCl₃)

13: FL-7292-64-1 ¹H NMR (600 MHz, CDCl₃): 2.88 (s, 6H); 3.19, 3.38 (br, m, 2H); 4.22 (m, 1H); 4.23 (m, 1H); 4.39 (m, 2H); 6.15 (br, s, 1H); 7.33 (t, J = 7.10 Hz, 2H); 7.41 (t, J = 6.77 Hz, 2H); 7.61 (t, J = 6.09 Hz, 2H); 7.78 (d, J = 4.0 Hz, 2H). ¹³C NMR (150.9 MHz, CDCl₃): 44 (br), 28.0 (br), 47.0 (s), 50.4 (s), 58.6 (s), 67.0 (s), 120.1 (s), 125.0 (br), 127.3 (s), 127.8 (s), 141.2 (s), 141.3 (s), 143.6 (s), 143.9 (s), 156.0 (s), 172.2 (s).MS: *m/z* 355 [M+H]⁺. HRMS calculated for C₂₀H₂₃N₂O₄: 355.1652. Found 355.1641. [α]_D²⁰ +76±3.93 (*c* 0.118, CHCl₃)

14: FL-7292-65-1 ¹H NMR (600 MHz, CDCl₃): 1.67, 187 (m, 2H); 1.90 (m, 2H); 2.71 (s, 6H); 2.81, 2.99 (m, 2H); 4.18 (m, 1H); 4.23 (t, J = 6.87 Hz, 1H); 4.32-4.38 (m, 2H); 7.33 (m, 2H); 7.41 (m, 2H); 7.65 (m, 2H); 7.78 (d, J = 7.3 Hz, 2H). ¹³C NMR (150.9 MHz, CDCl₃): 20.7 (s), 29.7 (s), 42.9 (s), 47.4 (s), 54.7 (s), 57.8 (s), 66.7 (s), 120.0 (s), 125.2 (s), 125.3 (s), 127.0 (s), 127.6 (s), 141.3 (s), 144.0 (s), 144.2 (s),

155.8 (s), 176.1 (s).MS: m/z 383 [M+H]⁺. HRMS calculated for C₂₂H₂₇N₂O₄: 383.1965. Found 383.1977. [α]_D²⁰ +116±1 (*c* 0.10, MeOH)

Synthesis of the Boc derivative of compound 9:



See literature procedure from Sakura *et al.*¹ using compound **9** as starting material. Yield ~100%.

¹H NMR (600 MHz, CDCl₃): 1.48 (br, s, 9H); 1.87, 2.25 (br, m, 2H); 2.66 (s, 3H); 3.03, 3.83 (br, m, 2H); 4.23 (t, J = 7.23 Hz, 1H); 4.33 (br, m, 1H); 4.39 (br, m, 2H); 6.19 (br, s, 1H); 7.31 (t, J = 7.59 Hz) 2H); 7.40 (t, J = 7.59 Hz, 2H); 7.61 (br, m, 2H); 7.76 (d, J = 7.3 Hz, 2H). ¹³C NMR (150.9 MHz, CDCl₃): 28.3 (s), 30.6 (s), 40.3 (s), 44.9 (s), 47.0 (s), 51.3 (s), 66.9 (s), 81.6 (s), 119.9 (s), 125.3 (s), 127.1 (s), 127.7 (s), 141.3 (s), 141.4 (s), 143.8 (s), 143.9 (s), 155.9 (s), 173.8 (br, s).

1. N. Sakura, T. Itoh, Y. Uchida, K. Ohki, K. Okimura, K. Chiba, Y. Sato and H. Sawanishi, *Bulletin of the Chemical Society of Japan*, 2004, **77**, 1915-1924.

```
Sample Name : FL_7292_57_1
Data File : D:\SHARE\DATA\RES_2014_11_26\A_FL_7292_57_1.D
```

```
Acquisition Method : D:\SHARE\METHODS\C1T13_G0008_U210P_1MLMIN.M
Method Info
```

nethou inito	. Mone spectred,		
Injection Date	: Wed, 26. Nov. 2014	Injection Time	: 23:26:15
Sample Location	1 : P2-D-05	Injection Number	: 1
Sample Name	: FL_7292_57_1	Injection Volume	: 20.0
Sample Info	:		



Injection date:Wed, 26 Nov. 2014 Page 1 of 2 Report Date:Fri, 28 Nov. 2014

Figure S1. Analytical LCMS of compound 4

```
Sample Name : FL_7292_36_1
Data File : D:\SHARE\DATA\RES_2014_11_26\A_FL_7292_36_1.D
```

```
Acquisition Method : D:\SHARE\METHODS\C1T13_G0008_U210P_1MLMIN.M
Method Info
```

Method Info	. Anone spectred/		
Injection Date	: Wed, 26. Nov. 2014	Injection Time	: 23:11:59
Sample Location	: P2-D-04	Injection Number	: 1
Sample Name	: FL_7292_36_1	Injection Volume	: 20.0
Sample Info			





Figure S2. Analytical LCMS of compound 7

```
Sample Name : FL_7292_35_1
Data File : D:\SHARE\DATA\RES_2014_11_26\A_FL_7292_35_1.D
```

```
Acquisition Method : D:\SHARE\METHODS\C1T13_G0008_U210P_1MLMIN.M
Method Info
```

Method Into	. None spectred/		
Injection Date	: Wed, 26. Nov. 2014	Injection Time	: 22:57:56
Sample Location	: P2-D-03	Injection Number	: 1
Sample Name	: FL_7292_35_1	Injection Volume	: 20.0
Sample Info	:		



Injection date:Wed, 26 Nov. 2014 Page 1 of 2 Report Date:Fri, 28 Nov. 2014

Figure S3. Analytical LCMS of compound 8

```
Sample Name : FL_7292_51_1
Data File : D:\SHARE\DATA\RES_2014_11_26\A_FL_7292_51_1.D
```

```
Acquisition Method : D:\SHARE\METHODS\C1T13_G0008_U210P_1MLMIN.MMethod Info: <None specified>Injection Date: Wed, 26. Nov. 2014Injection Time: 23:54:45Sample Location: P2-D-07Injection Number: 1Sample Name: FL_7292_51_1Injection Volume: 20.0Sample Info:
```



Injection date:Wed, 26 Nov. 2014 Page 1 of 2 Report Date:Fri, 28 Nov. 2014

Figure S4. Analytical LCMS of compound 9

Sample Name : FL_7292_52_1 Data File : D:\SHARE\DATA\RES_2014_11_26\A_FL_7292_52_1.D

Cooper Group: Institute for Molecular Biosciences, The University of Queensland

```
Acquisition Method : D:\SHARE\METHODS\C1T13_G0008_U210P_1MLMIN.MMethod Info: <None specified>Injection Date: Thu, 27. Nov. 2014Injection Time: 00:08:46Sample Location: P2-D-08Injection Number: 1Sample Name: FL_7292_52_1Injection Volume: 20.0Sample Info:::
```



Injection date:Thu, 27 Nov. 2014 Page 1 of 2 Report Date:Fri, 28 Nov. 2014

Figure S5. Analytical LCMS of compound 10

```
Sample Name : FL_7292_43_1
Data File : D:\SHARE\DATA\RES_2014_11_27\A_FL_7292_43_1C.D
```

```
Acquisition Method : D:\SHARE\METHODS\C1T13_G0008_U210P_1MLMIN.M
```

			_		-		
Method Info	:	<none specified=""></none>					
Injection Date	:	Fri, 28. Nov. 2014		Injection	Time	:	17:51:43
Sample Location	:	P2-A-01		Injection	Number	:	1
Sample Name	:	FL_7292_43_1		Injection	Volume	:	1.0
Sample Infe							



Injection date:Fri, 28 Nov. 2014 Page 1 of 2 Report Date:Fri, 28 Nov. 2014

Figure S6. Analytical LCMS of compound 11

Sample Name : FL_7292_67_1_frzON Data File : D:\SHARE\DATA\RES_2014_12_03\A_FL_7292_67_1_FRZON.D

Cooper Group: Institute for Molecular Biosciences, The University of Queensland

Acquisition Method	:	D:\SHARE\METHODS\C4T13_G0008_U210P.M				
Method Info	:	<none specified=""></none>				
Injection Date	:	Wed, 3. Dec. 2014	Injection	Time	:	12:41:59
Sample Location	:	P1-F-07	Injection	Number	:	1
Sample Name	:	FL_7292_67_1_frzON	Injection	Volume	:	5.0
Sample Info	:	Fmoc-Dab(Me2)-OH, 1.34mg,	/lmL			



Injection date:Wed, 3 Dec. 2014

Page 1 of 3

Report Date:Wed, 3 Dec. 2014

Figure S7. Analytical LCMS of compound 12

```
Sample Name : FL_7292_64_fra18
Data File : D:\SHARE\DATA\RES_2014_11_24\A_FL_7292_64_FRA18.D
```

```
Acquisition Method : D:\SHARE\METHODS\C4T13_G0008_U210P.MMethod InfoInjection DateSample Location: P1-F-01Sample Name: FL_7292_64_fra18Injection Volume: 30.0
```



Injection date:Tue, 25 Nov. 2014 Page 1 of 2 Report Date:Thu, 27 Nov. 2014

Figure S8. Analytical LCMS of compound 13

```
Sample Name : FL_7292_65_fra30
Data File : D:\SHARE\DATA\RES_2014_11_24\A_FL_7292_65_FRA30.D
```

```
Acquisition Method : D:\SHARE\METHODS\C4T13_G0008_U210P.MMethod Info: <None specified>Injection Date: Tue, 25. Nov. 2014Injection Time: 11:40:09Sample Location: P1-F-06Injection Number: 1Sample Name: FL_7292_65_fra30Injection Volume: 30.0
```



Page 1 of 3

Report Date:Tue, 25 Nov. 2014

Figure S9. Analytical LCMS of compound 14



Figure S10. 600 MHz ¹H NMR spectrum for **4** in CDCl₃ at 298K.



Figure S11. 150.9 MHz ¹³C j-mod NMR spectrum for **4** in CDCl₃ at 298K.



Figure S12. ^{1}H - ^{1}H COSY NMR spectrum for 4 in CDCl₃ at 298K



Figure S13. ¹H-¹³C HSQC NMR spectrum for **4** in CDCl₃ at 298K.



Figure S14. 600 MHz ¹H NMR spectrum for **7** in CDCl₃ at 298K.



Figure S15. ^{1}H - ^{1}H COSY NMR spectrum for 7 in CDCl₃ at 298K



Figure S16. $^{1}H^{-13}C$ HSQC NMR spectrum for 7 in CDCl₃ at 298K.



Figure S17. 600 MHz ¹H NMR spectrum for **8** in CDCl₃ at 298K.



Figure S18. ¹H-¹H COSY NMR spectrum for **8** in CDCl₃ at 298K



Figure S19. ¹H-¹³C HSQC NMR spectrum for **8** in CDCl₃ at 298K.



Figure S20. 600 MHz ¹H NMR spectrum for **9** in CDCl₃ at 298K.



Figure S21. 150.9 MHz ¹³C j-mod NMR spectrum for **9** in CDCl₃ at 298K.



Figure S22. ¹H-¹H COSY NMR spectrum for **9** in CDCl₃ at 298K



Figure S23. ¹H-¹³C HSQC NMR spectrum for **9** in CDCl₃ at 298K.



Figure S24. 600 MHz ¹H NMR spectrum for 10 in CDCl₃ at 298K.



Figure S25. 150.9 MHz ¹³C NMR spectrum for **10** in CDCl₃ at 298K.



Figure S26. 600 MHz ¹H NMR spectrum for 11 in CDCl₃ at 298K.



Figure S27. 150.9 MHz 13 C j-mod NMR spectrum for **11** in CDCl₃ at 298K.



Figure S28. ¹H-¹H COSY NMR spectrum for **11** in CDCl₃ at 298K



Figure S29. ¹H-¹³C HSQC NMR spectrum for **11** in CDCl₃ at 298K.



Figure S30. 600 MHz ¹H NMR spectrum for **12** in CDCl₃ at 298K.



Figure S31. 150.9 MHz 13 C NMR spectrum for **12** in CDCl₃ at 298K.



Figure S32. ¹H-¹H COSY NMR spectrum for **12** in CDCl₃ at 298K.



Figure S33. ¹H-¹³C HSQC NMR spectrum for **12** in CDCl₃ at 298K.



Figure S34. 600 MHz ¹H NMR spectrum for 13 in CDCl₃ at 298K.



Figure S35. 150.9 MHz ¹³C NMR spectrum for **13** in CDCl₃ at 298K.



Figure S36. ¹H-¹H COSY NMR spectrum for **13** in CDCl₃ at 298K.



Figure S37. ¹H-¹³C HSQC NMR spectrum for **13** in CDCl₃ at 298K.



Figure S38. 600 MHz ¹H NMR spectrum for 14 in CDCl₃ at 298K.



Figure S39. 150.9 MHz ¹³C NMR spectrum for **14** in CDCl₃ at 298K.



Figure S40. ¹H-¹³C HSQC NMR spectrum for **14** in CDCl₃ at 298K.



Figure S41. HRMS of compound 4



Figure S42. HRMS of compound 7



Figure S43. HRMS of compound 8



Figure S44. HRMS of compound 9



Figure S45. HRMS of compound 10



Figure S46. HRMS of compound 11



Figure S47. HRMS of compound 12



Figure S48. HRMS of compound 13



Figure S49. HRMS of compound 14